| ★ |  OTP Town Hall: Best Practices for Regulatory Interactions with OTP | U.S. Food and Drug Administration @us_fda | 644 | Estados Unidos | |
| 2 |  Draft Guidance: Leveraging Prior Knowledge in the Development of Human GT Products Incorporating GE | U.S. Food and Drug Administration @us_fda | 1.8K | Estados Unidos | 87 |
| 1 |  OTP Town Hall: Cell Therapy CMC Readiness for Late-Stage INDs | U.S. Food and Drug Administration @us_fda | 1.6K | Estados Unidos | 90 |
| 15 |  GDF2026 - Closing Remarks | U.S. Food and Drug Administration @us_fda | 595 | Estados Unidos | 85 |
| 4 |  GDF2026 - Updates on Nitrosamines/ Nitrosamine Mitigation Strategies for Pharmaceuticals | U.S. Food and Drug Administration @us_fda | 409 | Estados Unidos | 86 |
| 9 |  Conversatorio: Las actividades biotecnológicas y la industria farmacéutica | Secretaría de Innovación, Ciencia y Tecnología @innovacionarok | 313 | Argentina | 85 |
| 16 |  GDF2026 - Q&A Discussion Panel Eight | U.S. Food and Drug Administration @us_fda | 298 | Estados Unidos | 85 |
| 11 |  GDF2026 - Q&A Discussion Panel Six | U.S. Food and Drug Administration @us_fda | 292 | Estados Unidos | 85 |
| 6 |  GDF2026 - Q&A Discussion Panel Four and Day One Closing | U.S. Food and Drug Administration @us_fda | 187 | Estados Unidos | 86 |
| 8 |  GDF2026 - Bioequivalence (BE) Recommendations for Bridging Pre- and Post-Mitigation Formulations | U.S. Food and Drug Administration @us_fda | 160 | Estados Unidos | 85 |
| 14 |  GDF2026 - Best Practices for Safety Assessment of Nitrosamines in Generic Drugs | U.S. Food and Drug Administration @us_fda | 127 | Estados Unidos | 85 |
| 19 |  Hablemos de biotecnología un mundo de grandes oportunidades. Péptidos Bioactivos | Maestria en Biotecnologia Alimentaria ECBTI @maestriaenbiotecnologiaali2404 | 119 | — | 85 |
| 13 |  GDF2026 - Office of Pharmaceutical Quality (OPQ) Keynote | U.S. Food and Drug Administration @us_fda | 101 | Estados Unidos | 85 |
| 5 |  GDF2026 - Complex Drug Products – Quality Considerations for Generic Oligonucleotides | U.S. Food and Drug Administration @us_fda | 86 | Estados Unidos | 86 |
| 12 |  GDF2026 - Drug-Device Combination Products: A Quality Perspective | U.S. Food and Drug Administration @us_fda | 64 | Estados Unidos | 85 |
| 3 |  GDF2026 - Product-Specific Guidances (PSGs) in Action – Key Lessons and Common Questions | U.S. Food and Drug Administration @us_fda | 58 | Estados Unidos | 86 |
| 18 |  GDF2026 - Decoding PSGs for Complex Non-Oral Generics | U.S. Food and Drug Administration @us_fda | 49 | Estados Unidos | 85 |
| 20 |  GDF2026 - Orange Book: How Drug Product Listings are Added, Updated, and Maintained | U.S. Food and Drug Administration @us_fda | 39 | Estados Unidos | 85 |
| 7 |  GDF2026 - Controlled Correspondences: Minimizing Rejections, Maximizing Results | U.S. Food and Drug Administration @us_fda | 37 | Estados Unidos | 86 |
| 17 |  GDF2026 - Q&A Discussion Panel Five | U.S. Food and Drug Administration @us_fda | 29 | Estados Unidos | 85 |
| 10 |  Why Is Biotech Regulation So Complex? | Everyday Bioethics Expert @everydaybioethicsexpert | 3 | Estados Unidos | 85 |